Prior malignancy other than acute leukemia is allowed, provided it is in remission and there is no plan to treat the malignancy at the time of registration
Prior malignancy
Active malignancy (other than BRAF V mutation-negative melanoma) or malignancy within  years
A patient with a known other malignancy is eligible if there is a negligible risk for disease progression or death within one year, there is no active ongoing treatment for this malignancy, and the malignancy and/or any anticipated future treatments would not interfere with protocol-mandated evaluations at  year
Pts receiving active treatment or intervention for any other malignancy or pts who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within  months of starting study treatment.
Active malignancy other than the one for which AB- transplant is being performed within  months of enrollment.
Active cerebral/meningeal disease related to the underlying malignancy
Other active malignancy that warrants systemic therapy
Patients with suspected non-gynecologic malignancy, such as gastrointestinal
Presence of an active hematological malignancy.
No other active malignancy
Persistence/relapse at the time of study entry of the primary malignancy for which the transplant was performed, or any other active malignancy; patients with a history of relapsed malignancy who have achieved a remission at the time of evaluation for study participation will not be excluded
Patients must NOT have an active malignancy other than CD+ leukemia
Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment
Advanced measurable malignancy
Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment
No evidence of malignancy at the time of enrollment
Any active malignancy other than DLBCL
Other active malignancy
T-cell malignancy
Active malignancy (other than melanoma) or a prior malignancy within the past  years
No other active malignancy
Subjects must NOT have an active malignancy other than CD+ leukemia
No other active malignancy
Evidence of active malignancy other than CD+ malignancy
No other active malignancy
Other active malignancy receiving systemic therapy.
Active malignancy
No active or co-existing malignancy requiring chemotherapy or radiation within  months
MALIGNANCY CRITERIA:
Active CNS malignancy
Have active malignancy with the exception of nonmelanoma skin cancer, as determined by the investigator. Subjects who experience relapse or progression of their underlying malignancy (for which HSCT was performed), as determined by the investigator, are not to be enrolled.
Active cerebral/meningeal disease related to the underlying malignancy
Presence of an active hematological malignancy:
Presence of relapsed primary malignancy, or who have been treated for relapse after the alloHSCT was performed, or who may require rapid immune suppression withdrawal as pre-emergent treatment of early malignancy relapse.
Does not have any other active malignancy other than the one for which this transplant is indicated
Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment
Active treatment of a separate malignancy
Patients with prior malignancy successfully treated who are currently stable and on no active treatment are eligible
Has a malignancy:
No other active malignancy
No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ; patients with a prior history of malignancy are eligible if their malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer-directed therapies
Patient does NOT have an active malignancy other than NB
Active and uncontrolled relapse of malignancy.
Active and uncontrolled relapse of malignancy
Active and uncontrolled relapse of malignancy
Any other active malignancy
Active and uncontrolled relapse of malignancy
Uncontrolled, non-hematologic malignancy requiring active treatment
RECIPIENT: Presence of active malignancy in another organ system other than the hematopoietic, except when driven by viruses in which case the immune reconstitution after transplant may control the malignancy
Presence of malignancy.
Patients receiving active treatment or intervention for any other malignancy or patients who, at the investigators discretion, may require active treatment or intervention for any other malignancy within  months of starting study treatment
Presence of active malignancy in another organ system other than the hematopoietic system, except when driven by viruses in which case the immune reconstitution after transplant may control the malignancy
Resistant malignancy
Subject has another malignancy for which treatment is required.
Any malignancy
Has another active systemic malignancy treated with chemotherapy within  months before baseline (CD).
Have active malignancy with the exception of nonmelanoma skin cancer. Subjects who have had a hematopoietic stem cell transplant (HSCT) and who experience relapse or progression of the malignancy as per investigator's opinion are not to be enrolled.
Prior chemotherapy for any malignancy
Other malignancy requiring active treatment
Patient has another active malignancy
Patients who have an active nd malignancy requiring systemic treatment
Cerebral/meningeal disease related to the underlying malignancy that has not been definitively treated
No other current active malignancy requiring anticancer therapy.
Prior malignancy except for any of the following:
Prior treatment for lymphoid malignancy:
Active cerebral/meningeal disease related to the underlying malignancy.
History of tuberous sclerosis, lymphangioleiomyomatosis (LAM) or any active malignancy
Non-squamous malignancy of the penis
Patients with another uncontrolled malignancy; patients with a previous malignancy, treated curatively and without evidence of disease relapse are eligible
one or more of the following biomarkers of malignancy:
Prior malignancy.
Any active malignancy (other than BRAF-mutated melanoma) or a previous malignancy within the past  years
Cerebral/meningeal disease related to the underlying malignancy
Other active malignancy
Any other malignancy requiring treatment
Any active malignancy within  years that may alter the course of esophageal cancer; (apparently cured localized malignancy or advanced, but indolent malignancy with significantly more favorable prognosis are allowed)
No active co-existing malignancy with life expectancy less than  months due to that malignancy
Advanced measurable malignancy
another primary malignancy
Another primary malignancy
History of other malignancy (not including the underlying malignancy that was the indication for transplant)
History of another active uncontrolled malignancy at the time of study enrollment
No other active malignancy
Active morphologic relapse/progression of hematologic malignancy post transplantation.
Patients with more than one active malignancy at the time of enrollment.
Cerebral/meningeal disease related to the underlying malignancy
Subjects with another active malignancy
The patient has a recently diagnosed active malignancy requiring therapy
Subjects with no additional active malignancy within the last  years
Time since last therapy for treatment of underlying malignancy:
No active or co-existing malignancy (other than ALL or lymphoblastic lymphoma) with life expectancy less than  months due to that malignancy
Presence of active malignancy from an organ system other than hematopoietic
E . Prior malignancy.
Patients must have indications for treatment for their B cell malignancy at the time of enrollment on this trial
Other active malignancy
Active malignancy with the exception of any of the following:
Cerebral/meningeal disease related to underlying malignancy
Active malignancy other than the one for which the UCB transplant is being performed within  months of enrollment.
Patients with more than one type of active malignancy; an active malignancy is defined as one that is being treated with therapeutic intent and for which survival may be impacted, within  years of enrollment
Other currently active malignancy
History of other primary malignancy requiring systemic treatment within  months of protocol enrollment; patients must not have another active malignancy requiring treatment; patients must not be receiving chemotherapy or immunotherapy for another cancer
Other active malignancy
Patients must not have another, non-breast, active malignancy that requires treatment
Other active primary malignancy requiring treatment or limiting survival to =<  years prior to registration
Other active malignancy that requires therapy
Cerebral/meningeal disease related to the underlying malignancy, unless definitively treated.
Active and uncontrolled relapse of malignancy
Confirmed malignancy.
Does not have any other active malignancy other than the one for which this transplant is indicated
Active and uncontrolled relapse of malignancy
Patients receiving active treatment or intervention for any other malignancy or patients who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within  months of starting study treatment.
Malignancy OTHER than the BRAF mutant malignancy under study.
Does not have any other active malignancy other than the one for which this transplant is indicated
Patients who have a history of primary malignancy other than that being treated in this study, and currently requires active clinical intervention.
Any other malignancy that requires active treatment
History of any other malignancy requiring active treatment
No other currently active malignancy.
Other active malignancy.
Other malignancy requiring active treatment at time of study entry
Are undergoing cancer treatment for another malignancy
Have a diagnosed malignancy
Patients with evidence of persistent or active malignancy
Another active malignancy
Malignancy with bone instability
Patients with active malignancy; patient undergoing active treatment for malignancy in the adjuvant setting are eligible; treatment can include chemotherapy, targeted therapy or anti-hormonal therapy
Active and uncontrolled relapse of malignancy
Active hematologic malignancy (cancer that begins in blood-forming tissue, such as leukemia or lymphoma)
Active malignancy, metastatic disease, or anyone undergoing treatment for malignancy
Women with an active malignancy
Evidence of other active malignancy requiring treatment
Patients may have had a prior malignancy